Cargando…
Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts
It is becoming clear that combination strategies will be necessary to augment cancer immunotherapy. We report that combination anti-OX40/anti-CTLA-4 mAb immunotherapy improves survival by enhancing effector T cell expansion and function, even while inducing Th2 cytokine production. Furthermore, IL-4...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091104/ https://www.ncbi.nlm.nih.gov/pubmed/25050194 http://dx.doi.org/10.4161/onci.28245 |
| _version_ | 1782480737255030784 |
|---|---|
| author | Linch, Stefanie N Redmond, William L |
| author_facet | Linch, Stefanie N Redmond, William L |
| author_sort | Linch, Stefanie N |
| collection | PubMed |
| description | It is becoming clear that combination strategies will be necessary to augment cancer immunotherapy. We report that combination anti-OX40/anti-CTLA-4 mAb immunotherapy improves survival by enhancing effector T cell expansion and function, even while inducing Th2 cytokine production. Furthermore, IL-4 blockade in addition to combination therapy significantly improved anti-tumor efficacy. |
| format | Online Article Text |
| id | pubmed-4091104 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | Landes Bioscience |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-40911042015-03-17 Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts Linch, Stefanie N Redmond, William L Oncoimmunology Author's View It is becoming clear that combination strategies will be necessary to augment cancer immunotherapy. We report that combination anti-OX40/anti-CTLA-4 mAb immunotherapy improves survival by enhancing effector T cell expansion and function, even while inducing Th2 cytokine production. Furthermore, IL-4 blockade in addition to combination therapy significantly improved anti-tumor efficacy. Landes Bioscience 2014-03-17 /pmc/articles/PMC4091104/ /pubmed/25050194 http://dx.doi.org/10.4161/onci.28245 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
| spellingShingle | Author's View Linch, Stefanie N Redmond, William L Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts |
| title | Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts |
| title_full | Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts |
| title_fullStr | Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts |
| title_full_unstemmed | Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts |
| title_short | Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts |
| title_sort | combined ox40 ligation plus ctla-4 blockade: more than the sum of its parts |
| topic | Author's View |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091104/ https://www.ncbi.nlm.nih.gov/pubmed/25050194 http://dx.doi.org/10.4161/onci.28245 |
| work_keys_str_mv | AT linchstefanien combinedox40ligationplusctla4blockademorethanthesumofitsparts AT redmondwilliaml combinedox40ligationplusctla4blockademorethanthesumofitsparts |